NCT04099836View on ClinicalTrials.gov

Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib

PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

July 9, 2020

Primary Completion Date

November 13, 2022

Study Completion Date

June 15, 2023

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Atezolizumab

1200 mg IV every 3 weeks

DRUG

Bevacizumab

15 mg/kg IV every 3 weeks

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

Duke University
All Listed Sponsors
lead

Duke University

OTHER

NCT04099836 - Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib | Biotech Hunter | Biotech Hunter